Market portfolio

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression

Retrieved on: 
Tuesday, February 21, 2023
Extrapyramidal symptoms, Lurasidone, Somnolence, Serotonin, Intas Pharmaceuticals, Akathisia, Thought, Safety, Dopamine, Agitation, Schizophrenia, Behavior, Food, Accord, Anxiety, FDA, DSM-IV codes, Nausea, Market portfolio, US Foods, Tablet, Mental health, Pharmaceutical industry

DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.

Key Points: 
  • DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.
  • Lurasidone is an oral, atypical antipsychotic, which is a first-line treatment option for the management of schizophrenia in adults and adolescents.
  • "A generic option in mental health treatment provides more accessible healthcare to those who are in need."
  • Adverse reactions 2 of lurasidone for treatment of schizophrenia and bipolar depression include somnolence, akathisia, which is a feeling of restlessness, anxiety, and/or agitation, and extrapyramidal symptoms.

KraneShares Launches China Innovation Strategy While Expanding ETF Model Portfolio Offering to Leading Wealth Management Platforms

Retrieved on: 
Thursday, May 13, 2021
Investment, Market portfolio, Market risk, Exchange-traded funds, Invesco PowerShares

The portfolio dynamically adjusts weights to China and EM ex-China based on a proprietary, time-tested, and systematic methodology.

Key Points: 
  • The portfolio dynamically adjusts weights to China and EM ex-China based on a proprietary, time-tested, and systematic methodology.
  • The model can act as a comprehensive, stand-alone emerging market portfolio or as a complement to an existing strategy.\nKrane Dynamic China Growth Strategy provides investors core exposure to the brightest high-growth areas within China\'s economy.
  • Each of the ETF weights in the portfolio adjust according to a proprietary approach that evaluates real-time risk and reward trade-offs.
  • A prospectus containing this and other information with respect to any KraneShares ETFs that are a part of a model portfolio is available at www.kraneshares.com .

KraneShares Launches Krane All China Growth Strategy Model

Retrieved on: 
Tuesday, August 25, 2020
Finance, Money, Economy, Investment, Exchange-traded funds, KraneShares, Portfolio, Market portfolio

The Krane All-China Growth Strategy is the second strategy offered on KraneShares model portfolio platform.

Key Points: 
  • The Krane All-China Growth Strategy is the second strategy offered on KraneShares model portfolio platform.
  • The model can act as a comprehensive, stand-alone emerging market portfolio or as a complement to an existing strategy.
  • Krane Model Portfolios are hypothetical models for illustrative purposes only to demonstrate how certain ETFs, including KraneShares ETFs, can potentially fit into an investor's portfolio.
  • Investors should read the prospectus for each ETF that comprises a model portfolio carefully before investing based on a model portfolio.